Elevated UGT2B11 expression during the treatment of prostate cancer with cisplatin-based drugs may indicate that the body has developed resistance to these drugs and that androgen deprivation therapy or immunotherapy may be used to treat the prostate cancer (81, 82). This evidence concerns the gene UGT2B11 and Familial prostate cancer.